Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 224,728,541 papers from all fields of science
Search
Sign In
Create Free Account
Revlimid
Known as:
Celgene brand of lenalidomide
, Revimid
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Broader (1)
lenalidomide
lenalidomide 15 MG Oral Capsule [Revlimid]
lenalidomide 25 MG Oral Capsule [Revlimid]
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
A Novel Functional Composite Endpoint to Characterize Disease Progression in Patients with Secondary Progressive Multiple Sclerosis (S12.006)
L. Kappos
,
P. Vermersch
,
+12 authors
R. Fox
Neurology
2019
Corpus ID: 196563014
Objective: To evaluate a novel functional composite endpoint (CEP) based on disability progression and cognitive processing speed…
Expand
2019
2019
Neurofilament Light Chains as a Marker of Concurrent and Future Active Disease in Relapsing Multiple Sclerosis: An Analysis of Baseline Data From the Phase 3 Ozanimod Clinical Trials (S56.006)
S. Harris
,
G. Comi
,
+5 authors
L. Kappos
Neurology
2019
Corpus ID: 208433757
Objective: To explore the relationship between plasma neurofilament light chain (NfL) levels and relapsing multiple sclerosis…
Expand
Review
2015
Review
2015
OP0276 Risk of Serious Adverse Effects Associated with Different Biological and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: A Systematic Review…
S. Tarp
,
D. Furst
,
+9 authors
R. Christensen
2015
Corpus ID: 77396747
Background Large pivotal randomised controlled trials (RCTs) in rheumatoid arthritis (RA) increasingly employ “adaptive” designs…
Expand
2014
2014
Higher Expressions of PTH Receptor Type 1 and/or 2 in Bone Marrow Is Associated to Longer Survival in Newly Diagnosed Myeloma Patients Enrolled in Total Therapy 3
M. Zangari
,
Caleb K. Stein
,
+10 authors
B. Barlogie
2014
Corpus ID: 208477666
Higher Expressions of PTH Receptor Type 1 and/or 2 in Bone Marrow is Associated to Longer Survival in Newly Diagnosed Myeloma…
Expand
Review
2011
Review
2011
A 71-year-old woman with multiple myeloma status after stem cell transplantation.
L. Donato
,
S. Zeldenrust
,
D. Murray
,
J. Katzmann
Clinical Chemistry
2011
Corpus ID: 11225714
A 71-year-old woman with a 9-year history of monoclonal gammopathy of undetermined significance presented with anemia [hemoglobin…
Expand
2009
2009
T cells helping GVHD: take-away lessons.
D. Fowler
Blood
2009
Corpus ID: 3502378
Using double cytokine knockout donor CD4 cells, in this issue of Blood , Yi and colleagues help clarify the complex role of IFN…
Expand
2008
2008
Effect of bortezomib, cyclophosphamide, and filgrastim on complete remission rates and CD34+ stem cell collections in multiple myeloma (MM)
R. Niesvizky
,
J. Stern
,
+7 authors
M. Coleman
2008
Corpus ID: 74707770
8587 Background: Typical stem cell mobilization regimens in MM include G-CSF alone or with high-dose cyclophosphamide. Given the…
Expand
2006
2006
Lenolidamide (Revlimid), in Combination with Cyclophosphamide and Dexamethasone (CRD) Is an Effective Regimen for Heavily Pre-Treated Myeloma Patients.
G. Morgan
,
S. Schey
,
+6 authors
F. Davies
2006
Corpus ID: 58046165
Lenolidamide (Revlimid®) is an oral immunomodulatory drug that has been shown to be effective for the treatment of relapsed…
Expand
Review
2005
Review
2005
Cure of myeloma: hype or reality?
A. Fassas
,
John Shaughnessy
,
B. Barlogie
Bone Marrow Transplantation
2005
Corpus ID: 11526067
Summary:High-dose treatment (HDT) with autologous stem cell transplant(s) (ASCT) improved survival, when compared to standard…
Expand
2005
2005
Trasplante de células hematopoyéticas en mieloma múltiple
Jorge Vela-Ojeda
,
M. A. G. Ruiz-Esparza
2005
Corpus ID: 56546412
Multiple myeloma (MM) is the second most common hematologic malignancy, affecting approximately 14,000 new patients per year in…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE